Insmed (NASDAQ: INSM) insider plans 791-share Rule 144 stock sale

Rhea-AI Filing Summary

Insmed common stockholder files notice to sell shares under Rule 144. The filing covers a planned sale of 791 common shares of Insmed through Merrill Lynch on the NASDAQ, with an aggregate market value of 123,526 and 213,273,469 shares outstanding.

The shares to be sold were acquired on 02/01/2026 via stock plan activity from the issuer. The notice also lists recent sales by Roger Adsett during January 2026, including 2,059 common shares for gross proceeds of 358,616, 802 shares for 140,406, and 1,429 shares for 247,688.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 1800 K ST NW Suite 800 Washington DC 20006	791	123526	213273469	02/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/01/2026	Stock Plan Activity	Issuer			791	02/01/2026	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Roger Adsett 700 US Highway 202/206 Bridgewater NJ 08807	Common	01/08/2026	2059	358616
Roger Adsett 700 US Highway 202/206 Bridgewater NJ 08807	Common	01/07/2026	802	140406
Roger Adsett 700 US Highway 202/206 Bridgewater NJ 08807	Common	01/06/2026	1429	247688

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the latest Form 144 filing mean for Insmed (INSM) shareholders?

The Form 144 filing indicates an intent to sell 791 Insmed common shares through Merrill Lynch on NASDAQ. The filing is a regulatory notice under Rule 144 and does not by itself change Insmed’s operations or disclose new financial performance information.

How many Insmed (INSM) shares are covered in the new Rule 144 notice?

The notice covers 791 Insmed common shares planned for sale. These shares were acquired on 02/01/2026 through stock plan activity from the issuer and are to be sold via Merrill Lynch on the NASDAQ market as disclosed in the filing.

What recent insider sales are disclosed for Insmed (INSM) in this document?

The document lists January 2026 sales by Roger Adsett: 2,059 common shares on 01/08/2026 for gross proceeds of 358,616, 802 shares on 01/07/2026 for 140,406, and 1,429 shares on 01/06/2026 for 247,688, all in Insmed common stock.

How were the Insmed (INSM) shares in the new Form 144 acquired?

The 791 Insmed common shares covered by the notice were acquired on 02/01/2026 through stock plan activity from the issuer. The filing describes the nature of the acquisition as “Stock Plan Activity,” with the same date listed for acquisition and payment.

What market details are given for the planned Insmed (INSM) share sale?

The filing states the 791 Insmed common shares are to be sold through Merrill Lynch, with an aggregate market value of 123,526. The intended sale is on the NASDAQ exchange, with an approximate sale date of 02/03/2026 as disclosed in the securities information table.

How many Insmed (INSM) shares are reported outstanding in this filing?

The document reports 213,273,469 Insmed common shares outstanding in connection with the planned sale of 791 shares. This outstanding-share figure provides context for the size of the planned sale relative to the company’s overall common equity base.